

Khalid El Bairi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6421965/publications.pdf>

Version: 2024-02-01

48
papers

3,042
citations

516710

16
h-index

361022

35
g-index

52
all docs

52
docs citations

52
times ranked

3384
citing authors

#	ARTICLE	IF	CITATIONS
1	FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?. <i>Life</i> , 2022, 12, 81.	2.4	15
2	How to critically read a meta-analysis of clinical trials in neurooncology. <i>International Journal for Research and Ethics</i> , 2022, 5, .	0.0	0
3	Bevacizumab in metastatic colorectal cancer in a real-life setting â€“ toxicity profile, survival outcomes, and impact of tumor sidedness. <i>Wspolczesna Onkologia</i> , 2022, 26, 32-39.	1.4	5
4	Does the â€œDevilâ€ originate from the fallopian tubes?. <i>Seminars in Cancer Biology</i> , 2021, 77, 56-66.	9.6	7
5	Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 42-55.	9.6	10
6	The Emerging Role of Liquid Biopsy in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 2108.	2.4	20
7	The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. <i>Journal of Cancer Policy</i> , 2021, 28, 100285.	1.4	9
8	Tracing ovarian cancer research in Morocco: A bibliometric analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100777.	0.6	6
9	Ovarian cancer in Morocco: Time to act is now. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100857.	0.6	1
10	Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. <i>Frontiers in Oncology</i> , 2021, 11, 694821.	2.8	11
11	Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes. <i>Seminars in Cancer Biology</i> , 2021, 77, 1-2.	9.6	2
12	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. <i>Biomarkers in Medicine</i> , 2021, 15, 1289-1298.	1.4	12
13	Natural products in drug discovery: advances and opportunities. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 200-216.	46.4	1,990
14	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.		0
15	Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. , 2021, , 203-229.		0
16	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
17	Origins and Pathology of Epithelial Ovarian Cancer: A Brief Overview. , 2021, , 1-17.		0
18	The Advent of Circulating Tumor DNA in the Management of Ovarian Cancer. , 2021, , 167-185.		0

#	ARTICLE	IF	CITATIONS
19	Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. <i>Gastrointestinal Disorders</i> , 2021, 3, 1-22.	0.8	7
20	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	5.2	112
21	Practical Tools and Guidelines for Young Oncologists From Resource-Limited Settings to Publish Excellence and Advance Their Career. <i>JCO Global Oncology</i> , 2021, 7, 1668-1681.	1.8	2
22	Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
23	Repurposing anticancer drugs for the management of COVID-19. <i>European Journal of Cancer</i> , 2020, 141, 40-61.	2.8	59
24	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	5.2	16
25	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	5.2	90
26	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
27	The path to a better biomarker: application of a risk management framework for the implementation of PD-1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	4.5	142
28	Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 403-421.	3.1	7
29	The Power of Biomarkers in Transforming Patients Care in Gynecologic Oncology. <i>Current Drug Targets</i> , 2020, 21, 944-945.	2.1	1
30	Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?. <i>Current Drug Targets</i> , 2020, 21, 1026-1033.	2.1	6
31	Overview of Cost-Effectiveness and Limitations of Next-Generation Sequencing in Colorectal Cancer. , 2020, , 173-185.		0
32	Next-Generation Sequencing for Colorectal Cancer Management. , 2020, , 91-110.		0
33	Gut Microbiota, Next-Generation Sequencing, Immune-Checkpoint Inhibitors, and Colorectal Cancer: How Hot Is the Link?. , 2020, , 111-145.		1
34	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
35	The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer. , 2020, , 147-172.		1
36	Accessibility and affordability to trastuzumab for breast cancer patients: Voices of the global oncology community from ONCOLLEGE 001 survey, part 2. <i>Annals of Oncology</i> , 2019, 30, v673.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study. <i>Annals of Oncology</i> , 2019, 30, iii14.	1.2	1
38	The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 2492-2498.	5.6	24
39	Decoding colorectal cancer epigenomics. <i>Cancer Genetics</i> , 2018, 220, 49-76.	0.4	42
40	Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. <i>Cancer Medicine</i> , 2018, 7, 2221-2246.	2.8	8
41	Prediction of therapy response in ovarian cancer: Where are we now?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 233-266.	6.1	28
42	Anticancer potential of <i>Trigonella foenum graecum</i> : Cellular and molecular targets. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 479-491.	5.6	39
43	Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 105-118.	4.4	42
44	The Human Cancer Pathology Atlas: An open-access source for more than 900,000 Kaplan-Meier plots and 5 million cancer tissue images. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1438-1439.	5.6	4
45	Phytochemical, organoleptic and ferric reducing properties of essential oil and ethanolic extract from <i>Pistacia lentiscus</i> (L.). <i>Asian Pacific Journal of Tropical Disease</i> , 2016, 6, 305-310.	0.5	19
46	Toxicological properties of fenugreek (<i>Trigonella foenum graecum</i>). <i>Food and Chemical Toxicology</i> , 2016, 96, 145-154.	3.6	93
47	Natural products against cancer angiogenesis. <i>Tumor Biology</i> , 2016, 37, 14513-14536.	1.8	76
48	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. <i>Biomarker Insights</i> , 2016, 11, BMI.S33372.	2.5	23